{"id":"https://openalex.org/W4310106128","doi":"https://doi.org/10.1182/blood-2022-163456","title":"PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia","display_name":"PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310106128","doi":"https://doi.org/10.1182/blood-2022-163456"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-163456","doi":"https://doi.org/10.1182/blood-2022-163456","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-163456","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5072336042","display_name":"John O Mascarenhas","orcid":"https://orcid.org/0000-0002-8400-0483","observed_orcids":["https://orcid.org/0000-0002-8400-0483"]},"institutions":[{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Mascarenhas","raw_affiliation_strings":["1Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY","institution_ids":["https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["2Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Department of Hematology and Medical Oncology,, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008609620","display_name":"Jean\u2010Jacques Kiladjian","orcid":"https://orcid.org/0000-0002-8121-438X","observed_orcids":["https://orcid.org/0000-0002-8121-438X"]},"institutions":[{"id":"https://openalex.org/I4210144610","display_name":"H\u00f4pital Saint-Louis","ror":"https://ror.org/049am9t04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210144610"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Jacques Kiladjian","raw_affiliation_strings":["3Hopital Saint-Louis, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Hopital Saint-Louis, Paris, France","institution_ids":["https://openalex.org/I4210144610"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053983155","display_name":"Konstanze D\u00f6hner","orcid":"https://orcid.org/0000-0002-2261-9862","observed_orcids":["https://orcid.org/0000-0002-2261-9862"]},"institutions":[{"id":"https://openalex.org/I4210155144","display_name":"University Hospital Ulm","ror":"https://ror.org/05emabm63","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210155144"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Konstanze D\u00f6hner","raw_affiliation_strings":["4Ulm University Hospital, Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Ulm University Hospital, Ulm, Germany","institution_ids":["https://openalex.org/I4210155144"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103255098","display_name":"Sarah A. Buckley","orcid":"https://orcid.org/0000-0002-7041-8328","observed_orcids":["https://orcid.org/0000-0002-7041-8328"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sarah Buckley","raw_affiliation_strings":["5CTI BioPharma, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5CTI BioPharma, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060175597","display_name":"Jennifer A. Smith","orcid":"https://orcid.org/0000-0002-3575-5468","observed_orcids":["https://orcid.org/0000-0002-3575-5468","https://orcid.org/0000-0001-7717-2642"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer A. Smith","raw_affiliation_strings":["5CTI BioPharma, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5CTI BioPharma, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106487398","display_name":"Adam R. Craig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adam R Craig","raw_affiliation_strings":["5CTI BioPharma, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5CTI BioPharma, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091473676","display_name":"Simran Bedi Singh","orcid":"https://orcid.org/0000-0002-9564-8197","observed_orcids":["https://orcid.org/0000-0002-9564-8197"]},"institutions":[{"id":"https://openalex.org/I4210101701","display_name":"CTI BioPharma (United States)","ror":"https://ror.org/017bk0e71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simran Bedi Singh","raw_affiliation_strings":["6CTI Biopharma, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6CTI Biopharma, Seattle, WA","institution_ids":["https://openalex.org/I4210101701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["7Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046827092","display_name":"Claire N. Harrison","orcid":"https://orcid.org/0000-0002-3212-920X","observed_orcids":["https://orcid.org/0000-0002-3212-920X"]},"institutions":[{"id":"https://openalex.org/I1324925910","display_name":"St Thomas' Hospital","ror":"https://ror.org/054gk2851","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1324925910","https://openalex.org/I200166805","https://openalex.org/I4210111135"]},{"id":"https://openalex.org/I200166805","display_name":"Guy's and St Thomas' NHS Foundation Trust","ror":"https://ror.org/00j161312","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200166805"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire Harrison","raw_affiliation_strings":["8Guy's and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Guy's and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I1324925910","https://openalex.org/I200166805"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":2.6012,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.9141219,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":98},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"9592","last_page":"9594"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10746","display_name":"Platelet Disorders and Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pacritinib","display_name":"pacritinib","score":0.9539999961853027},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9670000076293945},{"id":"https://openalex.org/keywords/severe-thrombocytopenia","display_name":"severe thrombocytopenia","score":0.9259999990463257},{"id":"https://openalex.org/keywords/jak2-inhibitors","display_name":"JAK2 inhibitors","score":0.7870000004768372},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.8870000243186951},{"id":"https://openalex.org/keywords/bleeding-risk","display_name":"bleeding risk","score":0.5109999775886536},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.875},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.945781946182251},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8524919748306274},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6964603662490845},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.6749501824378967},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5657697319984436},{"id":"https://openalex.org/C2777753580","wikidata":"https://www.wikidata.org/wiki/Q1441305","display_name":"Constitutional symptoms","level":3,"score":0.5097491145133972},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4448768198490143},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4327712059020996},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.40317049622535706},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.36726897954940796},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2983476221561432},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.15293601155281067}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-163456","doi":"https://doi.org/10.1182/blood-2022-163456","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-163456","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3197428156","https://openalex.org/W2987026504","https://openalex.org/W2988980980","https://openalex.org/W4292552039","https://openalex.org/W3200542521","https://openalex.org/W3213716630","https://openalex.org/W2884593313","https://openalex.org/W4312906334","https://openalex.org/W4281775923","https://openalex.org/W2598479043"],"abstract_inverted_index":{"Background:":[0],"Myelofibrosis":[1,21],"is":[2,9,98,130,158,423],"a":[3,115,159,318,325,357,410],"rare":[4],"bone":[5,18],"marrow":[6,19],"disorder":[7],"that":[8,250],"characterized":[10],"by":[11],"clonal":[12],"proliferation":[13],"of":[14,26,50,54,88,137,167,202,210,248,253,315,369,406,420,427],"myeloid":[15],"cells":[16],"and":[17,34,47,56,59,78,114,135,152,218,289,304,321,361,377,401,404],"fibrosis.":[20],"belongs":[22],"to":[23,64,84,132,199,207,262,294,348,351,355],"the":[24,85,290,313,322,341,417,428],"group":[25],"BCR/ABL1":[27],"negative":[28],"myeloproliferative":[29],"neoplasms.":[30],"Patients":[31,258],"with":[32,43,66,76,103,123,150,173,178],"myelofibrosis":[33,77,108,151,177],"severe":[35,79,124,153],"thrombocytopenia":[36,80,90],"(platelet":[37],"counts":[38,189],"<50x109/L)":[39],"are":[40,81,95,259,312],"generally":[41],"older,":[42],"more":[44,274],"advanced":[45],"disease":[46],"increased":[48],"risk":[49,252],"bleeding,":[51],"higher":[52,67],"rates":[53],"anemia":[55],"complex/unfavorable":[57],"cytogenetics,":[58],"shortened":[60],"overall":[61,375],"survival":[62],"compared":[63],"patients":[65,75,122,149,316,350,407],"platelet":[68,188],"counts.":[69],"So":[70],"far,":[71],"treatment":[72],"options":[73],"for":[74,221,338],"limited":[82,193],"due":[83],"high":[86],"incidence":[87],"treatment-related":[89],"when":[91],"other":[92],"JAK":[93],"inhibitors":[94],"used.":[96],"Pacritinib":[97],"an":[99,285],"oral":[100],"JAK2/IRAK1/ACVR1":[101],"inhibitor":[102,196,216],"demonstrated":[104],"clinical":[105],"activity":[106],"in":[107,109,148,171,328,399],"two":[110],"phase":[111,116,164],"3":[112,165],"studies":[113],"2":[117],"dose-finding":[118],"study;":[119],"all":[120],"included":[121],"thrombocytopenia.":[125,154],"The":[126,309],"PACIFICA":[127,157,422],"trial":[128,166],"(NCT03165734)":[129],"designed":[131],"confirm":[133],"efficacy":[134],"safety":[136],"pacritinib":[138,168,264,360],"200":[139,265],"mg":[140,266],"twice":[141,267],"daily":[142,268],"vs":[143,169],"physician's":[144],"choice":[145],"(P/C)":[146],"therapy":[147,197],"Study":[155],"Design:":[156],"multinational,":[160],"multicenter,":[161],"randomized,":[162],"controlled":[163],"P/C":[170,270],"adults":[172],"primary":[174],"or":[175,181,205,214,235,246,255,269,280],"secondary":[176],"DIPSS":[179],"intermediate-":[180],"high-risk":[182],"disease,":[183],"ECOG":[184],"performance":[185],"status":[186],"0-2,":[187],"<50":[190],"x":[191],"109/L,":[192],"prior":[194],"JAK2":[195,212,215],"(up":[198],"270":[200],"days":[201,209],"low-dose":[203],"ruxolitinib":[204,272],"up":[206],"90":[208],"any":[211],"inhibitor),":[213],"na\u00efve,":[217],"not":[219],"candidates":[220],"stem":[222],"cell":[223],"transplant":[224],"(Figure":[225],"1).":[226],"Additional":[227],"exclusion":[228],"criteria":[229],"include":[230,365,381],"recent":[231],"grade":[232],"\u22652":[233],"cardiac":[234,413],"hemorrhagic":[236],"events,":[237],"left":[238],"ventricular":[239],"ejection":[240],"fraction":[241],"<50%,":[242],"QTc":[243,256],">450":[244],"msec,":[245],"use":[247],"medications":[249],"increase":[251],"hemorrhage":[254],"prolongation.":[257],"randomized":[260],"2:1":[261],"continuous":[263],"(low-dose":[271],"[no":[273],"than":[275],"10":[276],"mg/day],":[277],"danazol,":[278],"corticosteroids,":[279],"hydroxyurea).":[281],"Following":[282],"regulatory":[283],"feedback":[284],"amendment":[286],"was":[287,292,344],"initiated,":[288],"study":[291],"updated":[293],"have":[295],"co-primary":[296,310,339],"endpoints":[297,311,380],"involving":[298],"both":[299],"spleen":[300],"volume":[301],"reduction":[302,327],"(SVR)":[303],"total":[305],"symptom":[306],"score":[307],"(TSS).":[308],"proportion":[314,323,405],"achieving":[317,324],"\u226535%":[319],"SVR":[320],"\u226550%":[326],"modified":[329],"TSS":[330],"from":[331,346],"baseline":[332],"at":[333,372,430],"week":[334,373],"24.":[335],"To":[336],"account":[337],"endpoints,":[340],"sample":[342],"size":[343],"adjusted":[345],"348":[347],"399":[349],"provide":[352],"85%":[353],"power":[354],"detect":[356],"difference":[358],"between":[359],"P/C.":[362],"Secondary":[363],"objectives":[364],"Patient":[366],"Global":[367],"Impression":[368],"Change":[370],"response":[371],"24,":[374],"survival,":[376,383],"safety.":[378],"Tertiary":[379],"leukemia-free":[382],"hematologic":[384],"improvement,":[385],"fatigue":[386],"improvement":[387],"(based":[388],"on":[389],"PROMIS":[390],"v.1.0":[391],"-":[392,394],"Fatigue":[393],"Short":[395],"Form":[396],"7a),":[397],"changes":[398],"biomarkers":[400],"gene":[402],"expression,":[403],"who":[408],"experience":[409],"major":[411],"adverse":[412],"event":[414],"(MACE).":[415],"Given":[416],"US":[418,429],"approval":[419],"pacritinib,":[421],"currently":[424],"enrolling":[425],"outside":[426],"~100":[431],"sites":[432],"worldwide.":[433],"Figure":[434],"1View":[435,438],"largeDownload":[436,439],"PPTFigure":[437],"PPT":[440],"Close":[441],"modal":[442]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":5}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}